Treatment Resistant Depression (22-507 Arm B). Study Payment £1,500 + reasonable travel expenses

We are looking for patients with a diagnosis of Treatment Resistant Depression (TRD) i.e. depression that has not responded to two or more antidepressants, aged 18 to 75 to take part in a trial using 5-MeO-DMT. You must currently be taking Citalopram, Escitalopram, Fluoxetine or Sertraline, and be willing to discontinue any other antidepressant medications – we will assist you in doing this.

5-MeO-DMT is a ‘psychedelic’ drug, used both recreationally and in ceremonial settings due to its psychoactive properties. It is one of several controlled substances currently being investigated for their potential therapeutic properties. We are testing whether 5-MeO-DMT given with your usual antidepressant medication, together with psychological support is safe in patients with TRD to determine whether it is useful to investigate it further as a treatment for this condition.

This involves 3 psychedelic preparation sessions to prepare you for receiving the study drug, one 4 hour plus stay at HMR on the day you receive the study drug (via a nasal spray), and 3 integration sessions to discuss your experience of receiving the drug. This will be followed by a further 5 follow-up visits. In total, there will be up to 13 study visits, several of which can be done remotely via video call. The total time in the study can be up to 20 weeks.

Admissions regularly until December 2024.

The below form is for volunteers interested in the 22-507 study. For our other studies, please head to our general enquiry form page.